Business
Amarantus Receives Notices of Allowance from European Patent Office for MANF and CDNF in the Treatment of Retinal Disorders
Amarantus Receives Notices of Allowance from European Patent Office for MANF and CDNF in the Treatment of Retinal Disorders.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAmarantus Receives Notices of Allowance from European Patent Office for MANF and CDNF in the Treatment of Retinal Disorders\n\n\n\n\n\nAmarantus Receives Notices of Allowance from European Patent Office for MANF and CDNF in the Treatment of Retinal Disorders\nPR Newswire\nSAN FRANCISCO, February 29, 2016\n\n\n\nSAN FRANCISCO, February 29, 2016 /PRNewswire/ --\n\nAmarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that has received an Intent to Grant a Patent notice from the European Patent Officer for the Mesencephalilc Astrocyte-derived Neurotrophic Factor (MANF) method of use patent application entitled \"Method of Treatment for Retinal Disorders\". Amarantus expects the patent to issue later in 2016, adding additional key elements to our strong barrier-to-entry strategy for this potentially breakthrough technology targeting rare ophthalmological disorders.\n\nRecent key achievements in the MANF development program include:\n\n\nReceipt of orphan drug designation from the US FDA for the treatment of retinitis pigmentosa;\n\nReceipt of orphan drug designation from the US FDA for the treatment of retinal artery occlusion;\n\nReceipt of orphan drug designation from the EMA for the treatment of retinitis pigmentosa;\n\nSubmission of request for rare pediatric disease designation in the treatment of retinitis pigmentosa;\n\nInitiated process development with Catalent for manufacturing MANF protein in support of future first-in-man clinical studies.\n\n\n\n\"We are excited to see the continued progress for the Company's intellectual property strategy to protect our innovative technology for ophthalmological disorders,\" said Gerald E. Commissiong, President & CEO of Amarantus. \"MANF and CDNF define a unique family of proteins that act to protect cells and tissues from stress, via a mechanism that is of great interest to the scientific community. As a result of emerging scientific discoveries in the field, MANF's compelling biology, and solid progress on the regulatory front, we have begun to see a clear increase in business development interest around MANF.\"\n\nIn parallel, Amarantus has retained Wallachbeth Capital to evaluate strategic options for the MANF gene therapy program which may expa...